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Abstract 
For any immune-mediated disease, the main determinant of patient well-being is not the 
diagnosis itself, but the course the disease takes over time (prognosis)1-3. This varies 
substantially between patients for reasons that are poorly understood. Familial studies support 
a genetic contribution to prognosis4-6, but little evidence has been found for a proposed 
association between prognosis and the burden of susceptibility variants7-13. To better 
characterise how genetic variation influences disease prognosis, we performed a within-cases 
genome-wide association study in two cohorts of patients with Crohn's disease. We identified 
four genome-wide significant loci, none of which showed any association with disease 
susceptibility. Conversely, the aggregated effect of all 170 disease susceptibility loci was not 
associated with prognosis. Together, these data suggest that the genetic contribution to 
prognosis in Crohn’s disease is largely independent from the contribution to disease 
susceptibility, and point to a biology of prognosis that could provide new therapeutic 
opportunities. 
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Despite the success of genome-wide association studies (GWAS) in immune-mediated 
disease, a genetic contribution to aspects of disease other than susceptibility remains largely 
unstudied. One of the most important aspects from a clinical perspective is prognosis. For 
example in Crohn’s disease (CD), a relapsing-remitting form of inflammatory bowel disease 
(IBD), some patients experience frequent relapses and require treatment with increasingly 
potent immunosuppressants and/or surgery, while others achieve prolonged remission 
without any additional therapy1. Such variability in prognosis occurs in most immune-
mediated diseases2,3 and can make the difference between an excellent long-term outcome or 
progressive disability and death1-3.  
What determines prognosis is poorly understood, although a genetic contribution has been 
proposed based on similar patterns of disease behaviour often being observed within 
families4-6. To date, investigation into the genetics of prognosis has largely focused upon 
susceptibility variants7-9, based on the hypothesis that disease development and prognosis 
share a common genetic architecture14. Attempts to prove this hypothesis, however, have 
largely failed to demonstrate replicable associations10-13. For example, while NOD2 variants 
were initially associated with increased need for surgery in CD15, this has since been 
attributed to their association with ileal disease10,11,16 (the distribution of CD that is more 
commonly treated with surgery as the procedure carries a lower morbidity). Indeed, a sub-
phenotype analysis of IBD recently showed that susceptibility variants only explain a 
minority of phenotypic variance (and mainly to disease location) and that after conditioning 
on this there was little/no association with disease behaviour16.  
An alternative possibility is that the genetic contribution to prognosis might be distinct from 
that which confers disease susceptibility. Indeed, the idea of a separate biology of prognosis 
would fit with the observation that CD8 T-cell exhaustion correlates with outcome, but not 
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diagnosis, in multiple immune-mediated diseases17, and the identification of a SNP in 
FOXO3 that associates with prognosis, but not susceptibility, in several diseases including 
CD18. 
To better understand the genetic contribution to prognosis in CD, we performed a within-
cases GWAS in two CD cohorts and meta-analysed the results. To do this, we first identified 
patients at opposite ends of the prognostic spectrum for comparison. This approach enriches 
for alleles influencing prognosis and makes associated variants easier to detect because the 
odds ratios between extreme groups is higher than in the total sample19. Poor prognosis CD 
was defined as frequently-flaring, treatment-refractory disease that required consecutive 
treatment with >2 immunomodulators, or >2 abdominal surgeries, or a combination of the 
two18. Good prognosis CD was defined as indolent disease that had not required treatment 
with immunomodulators or surgery despite ≥4 years follow up18 (median 12 years). These 
definitions were applied to two cohorts of CD cases: the first from a previous GWAS20 (669 
poor prognosis cases, 389 good prognosis cases) and the second who were genotyped using 
UK Biobank Axiom arrays (1093 poor prognosis cases, 583 good prognosis cases). 
Altogether, 19.2% of cases had good prognosis CD and 32.2% had poor prognosis CD. 
Patients with an intermediate phenotype were excluded (n=2,794; 48.6%). At genome-wide 
significance (P < 5 x 10-8) the combined dataset had ≥80% power to detect variants (minor 
allele frequency [MAF] >20%) with odds ratios ≥1.33.  
Standard quality control checks for SNPs and samples were performed prior to imputation 
against the UK10K reference panel21 (Online Methods). Following imputation quality control 
(Online Methods, Supplementary Table 1) we tested 7.0 million and 7.5 million SNPs for 
association in cohorts 1 and 2 respectively, and meta-analysed the results. Cluster plots for 
associated SNPs were inspected to confirm the genotyping and, if imputed, were genotyped 
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to confirm the imputation (Online Methods, Supplementary Table 1). The genomic control 
inflation factor (λGC) was 1.023 in the combined analysis (Supplementary Fig. 1).  
Four loci passed genome-wide significance. These association signals were located in 
FOXO3, XACT, a region upstream of IGFBP1, and the MHC region (Table 1, Fig. 1A, 
Supplementary Table 2). The associated FOXO3 haplotype, which was previously identified 
in a candidate gene study using the same definitions18, regulates FOXO3 expression and 
controls a TGFβ1-dependent pathway that limits inflammatory responses in monocytes18. By 
genotyping or imputing 115 of 118 SNPs at this locus we mapped the peak association signal 
to an intronic region that contained enhancer marks (H3K4me1, H3K27ac, p300 binding) and 
transcription factor binding sites, consistent with the reported eQTL18 (Fig. 1B, 
Supplementary Fig. 2).  
The second association signal was located within XACT (Fig. 1C), a gene which encodes a 
long non-coding RNA that is only expressed from the active X chromosome22, and which 
resides over 630Kb from the nearest protein-coding gene. This association was detectable in 
both males and females (Supplementary Table 2). Although XACT has been studied in 
pluripotent stem cells22, its function in differentiated cells is unknown. Given the association 
with CD prognosis, however, it was striking that across multiple human tissues, XACT was 
most highly expressed within the intestine (Supplementary Fig. 3). 
The third association signal was located immediately upstream of IGFBP1 in a region that 
also contains IGFBP3 (Fig. 1D). The associated SNP at this locus (rs75764599:G>A, 
g.45899250G>A, hg19) was conspicuous for its lack of linkage disequilibrium (LD) with 
local SNPs, and had to be directly genotyped in cohort 1. Indeed, although long-range LD 
enabled imputation in cohort 2 (INFO_score 0.82), we genotyped the SNP in this cohort as 
well to confirm the association (Supplementary Table 1). This relative lack of LD is 
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sometimes observed at low frequency SNPs, and implies that rs75764599:G>A is likely to be 
the causal variant. IGFBP-1 and IGFBP-3 belong to a family of proteins that bind and 
prolong the half-lives of insulin-like growth factors I and II; proteins involved in processes 
including immunity and longevity23. The IGFBP1 locus has also been associated with anti-
citrullinated peptide antibodies in rheumatoid arthritis (RA)24. In RA, these antibodies predict 
a poor prognosis24, suggesting that this region might influence prognosis in CD and RA 
through a common pathway, as was shown for FOXO318. 
The final association signal was located in the MHC and stretched from HLA-B to the HLA-
DR genes (Fig. 1E). Despite the breadth of this signal, conditioning on the lead SNP revealed 
only one associated haplotype (Fig. 2A). To assess whether specific HLA alleles were 
responsible for this genetic association, we imputed classical 4-digit HLA alleles and 
detected associations at multiple class I and class II genes. Notably, all of the associated 
alleles belonged to a single multigene haplotype, "ancestral MHC 8.1" (AH8.1; Fig. 2B). 
Indeed, the strength of each allelic association correlated with how specific that allele was to 
AH8.1 (Supplementary Fig. 4). To clarify the contribution of AH8.1 to the genetic signal, we 
performed cross-conditioning to assess the residual associations when the SNP analysis was 
conditioned on the lead AH8.1 allele (HLA-B*08:01) and vice versa. In both directions, 
cross-conditioning abrogated any association, demonstrating that inheritance of AH8.1 was 
the major contributor to the genetic signal (Fig. 2C, Supplementary Table 3). Carriers of this 
haplotype are known to exhibit impaired responses to vaccination25 and defects in T-cell 
activation26,27, consistent with HLA-specific differences in antigen presentation. The 
increased frequency of this haplotype in good prognosis CD is therefore consistent with the 
notion that differential T-cell activation influences prognosis in immune-mediated disease17. 
Interestingly, no association was observed at HLA-DRB1*01:03, the HLA allele that has by 
far the strongest association with CD susceptibility of any HLA allele or SNP28 (Fig. 2B, 
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Supplementary Table 3). Similarly, the prognosis-associated MHC SNPs did not overlap with 
known disease susceptibility SNPs (Supplementary Fig. 5).  
We next investigated whether these associations were dependent on the criteria used to define 
prognosis. We found that the results could not be attributed to differences in disease location 
(Supplementary Table 4) or follow-up (Supplementary Table 5) and that 3 of the 4 
associations remained genome-wide significant if another definition of poor prognosis was 
used; abdominal surgery within 2 years of diagnosis29 (Supplementary Table 6). These 
associations are therefore likely to be involved in the biology that determines prognosis in 
CD, as was shown for FOXO318. To further explore this underlying biology, we examined 
whether genes tagged by an extended list of prognosis-associated SNPs (meta P < 10-5) were 
enriched within specific biological pathways (Online Methods). Strong enrichment was 
observed for pathways that regulate innate and adaptive immune responses, and responses to 
micro-organisms (Fig. 3A). Similar results were obtained if SNPs within the extended MHC 
were removed (Supplementary Table 7). To identify the cell-types involved, we examined for 
tissue-specific enrichment using an expression atlas of primary human cells30. Strong 
enrichment was observed in macrophages, followed by weaker signals in monocytes and 
dendritic cells (Fig. 3B, Supplementary Table 8). These mononuclear phagocytes play 
important roles in innate immunity and can initiate adaptive immune responses. Monocytes 
are also the cell-type in which the FOXO3 variant was biologically relevant18. Finally, we 
performed a protein-protein interaction analysis and found that many genes at associated loci 
interact either directly or indirectly, suggesting that there may be underlying cellular 
pathways that are important in disease prognosis (Supplementary Fig. 6).  
Interestingly, the 4 prognosis-associated haplotypes have not been associated with CD 
susceptibility in any GWAS, including a recent meta-analysis31 (Supplementary Table 9). 
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Accordingly, if they were to influence disease susceptibility, their effect size would be 
negligible. Conversely, after stratifying on disease location – to control for associations of 
some loci (e.g. NOD2) with distributions of CD that could affect assessments of clinical 
outcome10,11,16 – none of the 170 susceptibility variants31,32 were associated with prognosis, 
even if more relaxed statistical thresholds were used (Online Methods, Supplementary Table 
10). There was also no correlation between the power to detect effects at these SNPs and the 
observed P values, consistent with the hypothesis that susceptibility variants are not 
individually associated with prognosis (Supplementary Fig. 7). Similarly, genome-wide LD 
score regression confirmed that there was no significant overlap between the genetic bases of 
susceptibility and prognosis in CD if disease location was taken into account (Genetic 
Correlation = -0.51, Standard Error = 0.33, P = 0.121). 
To determine whether susceptibility variants might collectively influence prognosis, we 
calculated genetic risk scores for each patient, but again no significant differences were 
observed between the good and poor prognosis subgroups (Fig. 4). This result did not change 
if an extended list of CD-associated SNPs was used33, based on variants with meta P < 10-4 
(Supplementary Fig. 8). Together, these data suggest that susceptibility alleles do not 
meaningfully contribute to prognosis in CD, although a weak effect cannot be excluded due 
to the power of this analysis. If such an effect were to occur, however, it would be trivial 
compared to the effects of non-susceptibility loci that are associated with prognosis.  
Collectively, these data establish that the main genetic contribution to prognosis comes from 
loci that are distinct from those that drive disease susceptibility, and demonstrate that disease 
initiation is not only temporally distinct from active symptomatic disease, but also appears to 
be governed by separate genetics. This provides a starting point for better understanding the 
biology that determines prognosis in CD, and could lead to new and potentially improved 
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opportunities for therapeutic intervention. This also has implications for “personalised 
medicine”, although any genetic classifier would need to work in unselected CD cases (in 
whom the odds ratios at prognosis-associated variants will be smaller than were observed 
here). More generally, this work illustrates the value of re-analysing existing GWAS data 
using carefully selected subphenotypes. Indeed, providing sufficiently detailed clinical data 
are available, this approach should be broadly applicable, and could yield important new 
insights across multiple diseases.  
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Figure Legends 
 
Figure 1. Within-cases GWAS identifies four loci that are associated with prognosis in 
CD. 
(a) Plot of genome-wide association results. –log10 (P values) from the Wald statistic (logistic 
regression model) are plotted against chromosomal position for the combined association 
analysis (n = 1,762 poor prognosis CD, 972 good prognosis CD). Each point represents a 
SNP. Dotted red line indicates genome-wide significance threshold. The four new loci 
identified in this study are indicated. (b – e) Characteristics of the associated genomic 
regions. Upper panel, chromosomal position; middle panel, – log 10 (P values) for individual 
SNPs at each locus (left y axis), rate of recombination indicated by red line (right y axis); 
lower panel, gene position within the locus (in Panel e only selected genes from class I and II 
regions are shown for clarity). SNPs are coloured according to LD with the most associated 
variant. 
 
Figure 2. Association signal at the MHC is linked to the ancestral 8.1 haplotype 
(a) The residual MHC association after conditioning on the lead SNP (rs9279411). (b) Allelic 
associations at class I and II HLA genes. For each allele, odds ratios (OR), 95% confidence 
intervals, and P values are shown. The significance threshold was corrected for the number of 
independent tests (P < 2.5 x 10-4). Alleles that are components of the ancestral MHC AH8.1 
haplotype are shaded blue (full AH8.1 annotation: HLA A*01:01, C*07:01, B*08:01, 
DRB1*03:01, DRB3*01:01, DQA1*05:01, DQB1*02:01). HLA DRB1*0103 (the strongest 
IBD susceptibility allele, ref 28) is included for comparison (shaded grey). (c) The residual 
MHC association after cross-conditioning on the lead HLA allele (HLA-B*08:01). In panels 
a and c the -log10(P) of SNPs are plotted against chromosomal position. Only selected genes 
from class I and II regions are shown for clarity.  
 
Figure 3. Pathway analysis implicates regulation of immune responses and mononuclear 
phagocytes in CD prognosis  
(a) Horizontal bar plot of –log10 (P values) for the top 40 most enriched pathways in an 
analysis of 29 LD-pruned prognosis-associated SNPs (meta P < 1 x 10-5) across 1,751 
pathways annotated by Gene Ontology. (b) Bar plot of –log10 (P values) for 155 specific 
cell-types and conditions. Significant enrichment was observed in “monocyte-derived 
macrophages stimulated by M-CSF” and “monocyte-derived macrophages stimulated by M-
14 
 
CSF and interferon-gamma”. Other non-immune cell-types included neural, skin, lung, liver, 
stem cells, smooth muscle, stromal cells, bone marrow progenitors, endothelial and epithelial 
cells. Dotted lines represent Bonferroni-corrected significance thresholds. Analyses 
performed using SNPsea.  
 
Figure 4. Distribution of CD susceptibility alleles does not differ between the prognostic 
subgroups 
(a) "Box and Whiskers" plot of weighted Genetic Risk Scores between good prognosis and 
poor prognosis CD subgroups. Box represents median and interquartile range. Whiskers 
represent maximum and minimum values. Weights were based on beta coefficients calculated 
from odds ratios reported in Liu et al. (2015) for 170 CD susceptibility SNPs. n = 2,413 (b) 
Distribution of unweighted susceptibility allele counts between good prognosis and poor 
prognosis CD subgroups. Purple histogram bars represent the poor prognosis CD subgroup, 
yellow histogram bars represent the good prognosis CD subgroup. Statistical significance was 
assessed using unpaired two-tailed Student's t-test and was stratified for disease location. 
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Table 1. Association results for Crohn's disease prognosis loci 
 
 
 
Crohn's disease prognosis SNPs that met genome-wide significance (P < 5 × 10-8) in the 
combined analysis and nominal significance (P < 0.05) in both individual cohorts.  
The odds ratio is presented with respect to the minor allele and the risk of poor prognosis CD. 
Allele frequency data is presented for the good prognosis CD cohort. 
a AG deletion 
b Insertion 
c rs75764599 could not be imputed in cohort 1 because of low linkage disequilibrium at this 
locus, and was therefore directly genotyped using a TaqMan SNP genotyping assay. 
Chr, Chromosome; RAF, Risk Allele Frequency; ind., Indolent (good prognosis) CD; OR, 
odds ratio; 95% CI, 95% confidence interval for OR. 
 
  
Chr 
Position 
(Mb) 
SNP 
Risk 
allele 
RAF 
(ind.) 
OR 95% CI 
P 
cohort 1 
P 
cohort 2 
P 
combined 
Candidate 
gene or 
region 
X 112.9 rs5929166 A 0.03 0.33 0.23-0.48 1.12 x 10-5 5.01 x 10-5 4.56 x 10-9 XACT 
6 31.7 rs9279411 - a 0.15 0.60 0.50-0.71 1.35 x 10-5 7.22 x 10-5 5.46 x 10-9 MHC 
6 109.0 rs147856773 GTGb 0.12 0.57 0.47-0.70 7.76 x 10-4 4.29 x 10-6 1.31 x 10-8 FOXO3 
7 45.9 rs75764599 A 0.01 3.02 2.04-4.49 1.73 x 10-3c 6.25 x 10-6 4.32 x 10-8 
IGFBP1/ 
IGFBP3 
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Online Methods 
 
Study subjects  
Following ethical approval by Cambridge MREC (reference: 03/5/12) and Mater Health 
Services, Christchurch Hospital, two cohorts of unrelated CD cases of Northern European 
descent were considered (cohort 1: n = 1,748, cohort 2: n = 3,999). These cases were enrolled 
by the UK IBD Genetics Consortium (n = 5,521) and the University of Otago, New Zealand 
(n = 226) and all provided written informed consent. All cases were treated using a treatment 
strategy in which immunosuppression is incrementally escalated, but only in response to 
persistently flaring disease. Subgroups of patients with a poor prognosis or a good prognosis 
were identified using phenotype data. Poor prognosis CD was defined as disease that had 
required ≥ 2 immunomodulators or ≥ 2 abdominal surgeries or a combination of these (e.g. 1 
immunomodulator and 1 intestinal resection). Following quality control, 1762 cases met this 
definition (cohort 1: n = 669, cohort 2: n = 1,093). Good prognosis CD was defined as 
disease of  > 4 years duration (median 12 years) that had not required immunomodulators or 
intestinal resections. Following quality control, 972 cases met this definition (cohort 1: n = 
389, cohort 2: n = 583). Patients who did not meet either criteria, or where additional 
immunomodulators or surgery had only been required because of drug intolerance or 
complications of earlier surgery respectively, were excluded. 
 
Genotyping 
Samples in cohort 1 were genotyped as part of an earlier GWAS20. For this cohort, 
normalised intensity data were downloaded from the European Genome-Phenome Archive 
(EGA). Samples in cohort 2 were genotyped using the UK Axiom Biobank array 
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(Affymetrix). 27 SNPs (including rs75764599; IGFBP1 locus) demonstrated modest 
evidence of association in the cohort 2 (P < 5 x 10-5) but could not be imputed in cohort 1. 
These markers were directly genotyped in cohort 1 using TaqMan SNP genotyping assays. 
Imputed low frequency SNPs (MAF 1-5%) that showed evidence of association were also 
directly genotyped to confirm the imputation. 
 
Data processing  
1. Cohort 1 
Marker Quality Control: Markers that failed quality control (QC) checks in the original 
GWAS study20 were excluded. Genotypes were called from the normalised intensity data 
using CHIAMO. SNPs with overall missingness > 0.05 or differential missingness > 0.02 
were excluded. Because there were no healthy controls in this study (in whom deviation from 
Hardy–Weinberg equilibrium [HWE] is usually assessed34) only SNPs with marked deviation 
from HWE were excluded (P < 10-10).  
Sample Quality Control: Samples that failed QC criteria in the original study20 were 
excluded. The reported gender of each case was checked against the genotype-inferred 
gender using Plink35. Samples with gender mismatch were excluded. Samples with a 
genotype missingness rate > 0.05 or heterozygosity rate greater than two standard deviations 
from the mean were also excluded34. To identify related samples, 119,811 LD-independent 
SNPs were selected and pairwise identity-by-descent was estimated using Plink35 (pi-hat 
threshold 0.1875). For any related samples, one case was randomly selected and kept and the 
other(s) were excluded. 
18 
 
Geographical outliers. A pruned version of the dataset, containing 56,919 LD-independent 
SNPs was merged with the 1000 Genomes Project dataset36. Principal Component Analysis 
(PCA) was used to identify and exclude geographical outliers. 
In total, 62 samples in cohort 1 failed QC. 
 
2. Cohort 2 
In addition to standard pre-GWA QC measures, additional quality controls specific to the 
Axiom genotyping array were recommended by the manufacturers (Affymetrix). These were 
performed prior to standard QC.  
Axiom-specific sample QC. Genotyping arrays were batched by processing date, and analysed 
separately as per the manufacturer’s instructions. The Dish Quality Control (DQC) metric 
(the recommended quality metric for Axiom genotyping arrays) was computed for each 
sample. Samples with DQC < 0.82 were excluded, as per the manufacturer's 
recommendations. Samples with a preliminary call rate ≤ 97% at a set of 20,000 validated 
autosomal markers were also excluded. Plates with an average preliminary call rate of 
passing samples < 98.5% were excluded, as per the manufacturer's recommendations.  
Axiom-specific marker QC: Genotypes were called separately for each batch using the apt-
probeset-genotype utility with default parameters. QC metrics for each marker were 
computed using the Ps_Metrics function in SNPolisher in R and used to classify markers 
based on the quality of signal. Markers classified in categories PolyHighRes, NoMinorHom 
and MonoHighRes were selected for further analysis. 500 probe-sets from each selected 
category were randomly selected and inspected to confirm the classification. 
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Standard sample and marker quality control. In addition to the Axiom-specific QC measures, 
standard pre-GWA QC steps were applied as described for cohort 1. 
In total, 71 samples in cohort 2 failed QC. 
 
Genotype imputation 
Genotype imputation was performed using IMPUTE237 after estimating haplotypes with 
SHAPEIT238 and the UK10K reference panel21. Default SHAPEIT2 parameters were 
modified (-states 500 -burn 10 -prune 10 -main 50) to improve accuracy by increasing the 
number of conditioning states39. Samples from each cohort were pre-phased and imputed in a 
single batch, to avoid batch effects attributable to the imputation process. To make the 
computation feasible, the dataset was divided into ~3000 overlapping 1Mb regions. 
IMPUTE2 was used with the option -buffer 2000 to leverage on a genomic window of 5Mb 
(1Mb analysed region plus 2 Mb buffer regions on either side). Results were controlled and 
reassembled in R. Phasing and imputation of the X Chromosome was performed using the -
chrX flag and the gender of each sample was provided. Imputed variants with MAF < 1% 
and/or INFO score < 0.8 where excluded.  To estimate imputation accuracy, imputed 
genotype calls at 99,124 SNPs were compared with direct genotyping data in 880 cases 
(Illumina Immunochip32). Mean concordance was 99.3% (Supplementary Table 1).  
 
Power calculations 
Power calculations were performed using the GPC function in the GeneticsDesign package in 
R. The prevalence of poor prognosis CD was calculated using the total number of poor 
prognosis cases (prior to QC) as a proportion of all of the cases considered (1,848/5,747). 
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Statistical analysis 
Association tests and meta-analysis. A frequentist association test between genotypes and the 
binary phenotype was performed using SNPTEST under an additive genetic model. Ten 
principal components were included as covariates in the logistic regression model in order to 
control for population stratification, although genomic inflation was acceptable even before 
this correction was applied (unadjusted λGC <1.05). The λGC in the combined analysis 
following principal component correction was 1.023 (1.012 and 1.022 for cohorts 1 and 2 
respectively; Supplementary Fig. 1). Genotype uncertainty, generated by the calling algorithm 
or by imputation, was factored into the association test using the -method score option in 
SNPTEST. For markers on the X chromosome, the association test was performed assuming 
a standard model of complete X inactivation, an equal effect size in men and women, and 
providing gender information for each sample. In this model, male genotypes were encoded 
as 0 / 1 and females as 0 / ½ / 1. . Meta-analysis was performed using a fixed-effects model 
and default parameters in META40. Cluster plots for associated SNPs were visually inspected 
to verify genotype calls and, if imputed, were directly genotyped to confirm the result 
(TaqMan SNP Genotyping Assay, Supplementary Table 1). Cross-conditioning analysis of 
the MHC region was performed in SNPTEST using the combined dataset and including the 
lead HLA allele (HLA-B*08:01) as a covariate. Cross-conditioning analysis of HLA allelic 
associations was performed using logistic regression in the combined dataset and including 
genotype at the lead SNP (rs9279411) as a covariate (Supplementary Table 2). 
Zero-inflated Poisson regression analysis. To determine whether the results were influenced 
by differences in the length of follow up in the poor prognosis CD subgroup, a zero-inflated 
Poisson regression model was fitted to the count data of total treatment escalations per patient 
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(immunomodulators and surgery) using the zeroinfl function in pscl in R41. This was 
confirmed to be the most appropriate model for the data using Vuong's closeness test. Poisson 
regression was then performed and disease duration was included within the regression terms 
to assess if prognosis-associated SNPs were associated with treatment escalation rate 
independent of disease duration (Supplementary Table 5).  
Disease-associated SNP analysis. 170 CD susceptibility loci were identified from a recent 
large meta-analysis31 (Supplementary Table 10). Because several of these SNPs have been 
associated with specific anatomical distributions of CD, which can confound assessments of 
disease course if there are any differences in disease location between the prognostic 
subgroups7,10,11,16, we stratified this analysis for disease location in addition to the top 10 
principal components. Disease location data was available for 88.2% of samples (n = 2,413). 
Samples for whom disease location data were not available were excluded. To improve the 
power to detect smaller effects, a candidate gene analysis was performed including only the 
170 susceptibility variants, and correcting for multiple testing using the Bonferroni method or 
false discovery rate (FDR q < 0.25). This analysis was predicted to have ≥ 80% power to 
detect variants (MAF > 20%) with odds ratios ≥ 1.25, and should have been adequately 
powered to identify effects that were previously reported in unstratified analyses42. For this 
analysis, approximate Bayes factors were also calculated using the method described in ref 
43. The prior variance was based on there being an equivalent effect size as was observed in a 
recent susceptibility meta-analysis31.   
HLA allelic association analysis. The MHC region on chromosome 6 (chr6:25092012-
35092011) was extracted from the post-QC dataset and used to impute 199 classical HLA 
alleles using HLA*IMP:0244. Alleles imputed with confidence > 80% were retained for 
association testing. Imputed HLA alleles for both cohorts were combined into a single dataset 
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and univariate logistic regression was performed without covariates. Nominal P values were 
calculated from the Wald statistic45. The statistical significance threshold was adjusted using 
a Bonferroni correction for multiple testing. Reference allele frequency and haplotype data 
was obtained from the National Bone Marrow Donor Program 
https://bioinformatics.bethematchclinical.org/hla-resources/haplotype-frequencies (Six-Locus 
High Resolution HLA A∼C∼B∼DRB3/4/5∼DRB1∼DQB1 Frequencies). 
RNA Expression Analysis 
Raw RNA sequencing data (fastq files) were downloaded from publically available 
repositories: GSE4532646 (GEO) and E-MTAB-513 (ArrayExpress). Reads were aligned to 
the UCSC Refseq genes (hg19) using Star47 and quantified, normalised and analysed using 
Cufflinks v2.2.148 (Seven Bridges Genomics platform, https://www.sbgenomics.com/). 
Pathway Analysis 
(i) SNPsea: Pathways and cell-types that were likely to be affected by prognosis-
associated loci, were identified used SNPsea49. In separate analyses we assessed 
the enrichment of an LD-pruned list of 34 prognosis-associated SNPs (r2 > 0.6, 
meta P < 10-5) in 1751 Gene Ontology pathways and 155 primary human cell-
types and conditions (comprising 745 individual samples)30. Empirical P values 
were calculated by permutation using null SNP sets (matched for the number of 
linked genes) from a list of LD-pruned SNPs (subset of SNPs in 1000 Genomes 
Project). Reference data including the null SNP sets, NCBI gene intervals, Gene 
Ontology pathways, and SNP linkage interval data were provided in SNPsea 
software.  
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(ii) DAPPLE (Disease Association Protein-Protein Link Evaluator): Physical 
interactions between proteins encoded by genes at prognosis-associated loci were 
assessed using DAPPLE50, based on a list of SNPs with meta P < 10-4.   
Genetic risk scores. Weighted Genetic Risk Scores were calculated using the PredictABEL 
package51 using SNPs and their corresponding beta coefficients as reported in Liu et al. 2015 
(for the 170 CD GWAS hits; Fig. 4) or Wei et al. 2013 (who generated a 573 SNP classifier 
from 10,799 SNPs with P < 1 x 10-4 in a cohort of ~17,000 CD cases and ~22,000 controls; 
Supplementary Fig. 8). Unweighted susceptibility allele counts were calculated by summing 
the number of risk alleles without including a beta coefficient. Statistical significance was 
assessed using an unpaired two-tailed Student's t test. Data were stratified for disease location 
and the results were combined using META40. 
 
LD score regression 
LD score regression52 was performed using LD Hub53, a centralised database of summary-
level GWAS results that provides a web interface for LD score regression. For this analysis 
the MHC region was removed – as recommended by LD Hub (because its complex genetic 
architecture is not adequately captured by simple LD). Genetic correlation was then 
calculated between the prognosis meta-analysis results (stratified for disease location) and the 
summary statistics from the largest CD susceptibility meta-analysis to date31.  
 
Data availability  
Genotyping data that support the findings of this study have been deposited in the European 
Genome-phenome Archive (EGA, https://www.ebi.ac.uk/ega/home) with the accession 
codes: EGAD00000000005 [cohort 1] and EGAS00001002147 [cohort 2]). Summary 
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statistics can also be downloaded from 
ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/human/2016-10-
12/CD_prognosis_GWA_results.csv.zip. 
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